Actavis terminates biosimilar insulin JV as Sanofi throws its hat in the ring
This article was originally published in Scrip
Executive Summary
Actavis has terminated a joint venture agreement for developing biosimilar insulins with Bioton of Poland. This comes as Sanofi goes public with its own biosimilar insulin plans.